US FDA Advisory Committee Votes in Support of Trials Designed to Evaluate Jemperli (Dostarlimab-Gxly) as a Potential Treatment for Mismatch Repair-Deficient/Microsatellite Instability-High Locally Advanced Rectal Cancer

GSK plc announced that the US FDA Oncologic Drugs Advisory Committee voted 8 to 5 in support of the question whether data from two proposed single-arm trials will be “sufficient to characterize the benefits and risks” of Jemperli in the curative-intent setting for patients with mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer.